Disease · MONDO_0002305

thrombophilia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. thrombophilia. Diseases, record MONDO_0002305. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002305

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: thrombophilia; Open Targets
Open Targets ID: MONDO_0002305; Open Targets
Other names: excessive blood clotting, hypercoagulability, hypercoagulability state, hypercoagulable; Open Targets
Disease Ontology: DOID:2452; Disease Ontology
MeSH: D019851; MeSH
NCI Thesaurus: C84479; NCI Thesaurus
Orphanet: ORPHA:64738; Orphanet
Highest stage of its drugs: Approval, for 2 of its 9 drugs, from PMDA; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ANTITHROMBIN GAMMA	CHEMBL4594458		Approval	PMDA	1	0	0	Drugs and targets
PROTEIN C CONCENTRATE (HUMAN)	CHEMBL5315087		Approval	PMDA	1	0	0	Drugs and targets
EDOXABAN	CHEMBL1269025	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
ENOXAPARIN	CHEMBL1201685	Oligosaccharide	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ISOQUERCETIN	CHEMBL250450	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
QUERCETIN	CHEMBL50	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
CLOPIDOGREL	CHEMBL1771	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
FONDAPARINUX	CHEMBL1201202	Oligosaccharide	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
HEPARIN	CHEMBL4650299	Oligosaccharide	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SERPINC1	Antithrombin-III	2	Antithrombin-III activator	Unknown	https://conductscience.org/library/genes/462	Drugs and targets
F10	Coagulation factor X	1	Coagulation factor X inhibitor	Phase 2/3	https://conductscience.org/library/genes/2159	Drugs and targets
P2RY12	P2Y purinoceptor 12	1	Purinergic receptor P2Y12 antagonist	Unknown	https://conductscience.org/library/genes/64805	Drugs and targets
PROC	Vitamin K-dependent protein C	1	Vitamin K-dependent protein C exogenous protein	Approval	https://conductscience.org/library/genes/5624	Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01722669	Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States	Early phase 1	38	2020-10-12	Healthy	ISOQUERCETIN, QUERCETIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00644657	The Effect of Clopidogrel on Coated-Platelets in Patients Undergoing Cardiac Catheterization	Not applicable	27	2011-10-07	Coronary Artery Disease, Chest Pain	CLOPIDOGREL	Its record names the disease	ClinicalTrials.gov
NCT04359212	Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19		90		COVID-19 Disease, Thromboembolism, Venous	FONDAPARINUX, HEPARIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02448901	Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography		40		Heart Failure	EDOXABAN	Its record names the disease	ClinicalTrials.gov
NCT03570281	Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study)	Phase 2/3	40		Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban)	EDOXABAN, ENOXAPARIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38429253	DERIVED	1	PubMed
35244208	DERIVED	1	PubMed
33502773	DERIVED	1	PubMed
28097231	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002305

GET https://conductscience.org/api/diseases/v1/MONDO_0002305/drugs

API reference For AI assistants